(Q47836201)

6 February 2018

title

Rubella revisited: where are we on the road to disease elimination in Central Europe? (English)

1 reference

6 February 2018

1 reference

1 reference

11

1 reference

6 February 2018

Marko Pokorn

object named as

Marko Pokorn

10

0 references

Darko Richter

object named as

Darko Richter

12

0 references

author name string

Vytautas Usonis

1

1 reference

6 February 2018

Ioana Anca

2

1 reference

6 February 2018

Francis André

3

1 reference

6 February 2018

Roman Chlibek

4

1 reference

6 February 2018

Milan Cižman

5

1 reference

6 February 2018

Inga Ivaskeviciene

6

1 reference

6 February 2018

Atanas Mangarov

7

1 reference

6 February 2018

Zsófia Mészner

8

1 reference

6 February 2018

Penka Perenovska

9

1 reference

6 February 2018

Nuran Salman

13

1 reference

6 February 2018

Pavol Simurka

14

1 reference

6 February 2018

Eda Tamm

15

1 reference

6 February 2018

Goran Tešović

16

1 reference

6 February 2018

Ingrid Urbančíková

17

1 reference

6 February 2018

language of work or name

English

0 references

publication date

3 October 2011

1 reference

6 February 2018

published in

Vaccine

1 reference

6 February 2018

volume

29

1 reference

6 February 2018

issue

49

1 reference

6 February 2018

page(s)

9141-9147

1 reference

6 February 2018

The History of Rubella and Rubella Vaccination Leading to Elimination

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.104

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.104

The epidemiological profile of rubella and congenital rubella syndrome in the United States, 1998-2004: the evidence for absence of endemic transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.104

Twenty years' experience of rubella vaccination in Sweden: 10 years of selective vaccination (of 12-year-old girls and of women postpartum) and 13 years of a general two-dose vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.104

Causes of morbilliform rash in a highly immunised English population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.104

A large rubella outbreak, Romania--2003.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.104

Vaccines for measles, mumps and rubella in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.104

A new challenge for Europe: introducing a pediatric quadrivalent vaccine for measles, mumps, rubella, and varicella

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.104

Comparison of rubella seroepidemiology in 17 countries: progress towards international disease control targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.104

The prevalence of anti-rubella antibodies in women of childbearing age in Poland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.104

Rubella seroprevalence in women in the reproductive period, Mersin, Turkey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.104

Seroprevalence of Toxoplasma gondii, rubella and cytomegalovirus among pregnant women in western region of Turkey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.104

Prevention of congenital rubella infection: a challenge for every country in Europe.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.104

10.1016/J.VACCINE.2011.09.104

7 January 2021

Identifiers

DOI

1 reference

6 February 2018

1 reference

6 February 2018